WO1995025516A1 - Pharmaceutical formulations containing beta-lactam antibiotics and an alkyl sulphate surfactant - Google Patents

Pharmaceutical formulations containing beta-lactam antibiotics and an alkyl sulphate surfactant Download PDF

Info

Publication number
WO1995025516A1
WO1995025516A1 PCT/EP1995/001039 EP9501039W WO9525516A1 WO 1995025516 A1 WO1995025516 A1 WO 1995025516A1 EP 9501039 W EP9501039 W EP 9501039W WO 9525516 A1 WO9525516 A1 WO 9525516A1
Authority
WO
WIPO (PCT)
Prior art keywords
beta
granule
pharmaceutical
granules
group
Prior art date
Application number
PCT/EP1995/001039
Other languages
French (fr)
Inventor
Anthony Guy Hatton
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Priority to EP95928859A priority Critical patent/EP0751771A1/en
Priority to JP7524382A priority patent/JPH09510470A/en
Publication of WO1995025516A1 publication Critical patent/WO1995025516A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Definitions

  • This invention relates to pharmaceutical formulations, in particular to beta-lactam antibiotic formulations in the form of substantially spherical granules.
  • the active ingredient comprises a beta-lactam antibiotic and/or beta-lactamase inhibitor
  • it is frequently necessary to provide the formulation in the form of granules for example for making up into tablets, capsules or sachet formulations etc.
  • it is desirable that the granules are substantially spherical.
  • substantially spherical as used herein is intended to include spherical, ellipsoidal, e.g. of eccentricity up to no more than 2, preferably up to no more than 1.5, oblate spheroidal, e.g. having its longest axes up to no more than 2 times, preferably up to no more than 1.5 times longer than its shortest axis, polyhedral with at least 12 faces having predominantly curved rather than angular edges, and substantially equiaxial.
  • the term also includes the shape of what are known in the art as "maru s".
  • the terms "spheronised” and “spheronisation” are terms of the art.
  • substantially spherical granules when granules of relatively water soluble antibiotics, and of beta-lactamase inhibitors such as salts of clavulanic acid such as potassium clavulanate are to be coated, as the angles of angular granules can present weak points in the coat via which the antibiotic or inhibitor may be leached out. Problems have been encountered in providing such antibiotics and beta-lactamase inhibitors in the form of granules, particularly in the form of substantially spherical granules.
  • a pharmaceutical granule comprising: an active ingredient which comprises one or more beta-lactam antibiotics and/or one or more beta-lactamase inhibitors; and one or more surfactants which are Group I or Group II metal (CJO-17) alkyl sulphates.
  • the invention further provides a process for the preparation of a pharmaceutical granule, comprising admixing one or more beta-lactam antibiotics, and/or one or more beta-lactamase inhibitors with one or more surfactants which are Group I or Group ⁇ metal (C ⁇ o-17) alkyl sulphates, and then granulating the mixture.
  • a pharmaceutical granule comprising admixing one or more beta-lactam antibiotics, and/or one or more beta-lactamase inhibitors with one or more surfactants which are Group I or Group ⁇ metal (C ⁇ o-17) alkyl sulphates, and then granulating the mixture.
  • the granule is primarily intended for oral administration, and consequently preferred antibiotics are orally absorbed penicillins (which term includes penicillins penems, penams, carbapenems etc.) or cephalosporins.
  • Preferred beta-lactam antibiotics are amoxyc ⁇ lin, for example as its trihydrate, and ampicillin.
  • a preferred beta-lactamase inhibitor is a salt of clavulanic acid, especially group I metal salts thereof such as potassium clavulanate.
  • a preferred combination of beta-lactamase inhibitor and antibiotic is potassium clavulanate : amoxycillin, as amoxycillin trihydrate or sodium amoxycillin, for example as crystalline anhydrous sodium amoxycillin as described in EP 0131147.
  • a preferred ratio of clavulanate : amoxycillin is in the range 1 : 1 to 1 : 12 inclusive, particularly 1 : 2 to 1: 8, expressed in terms of weight ratios of the free acids.
  • the Group I or Group ⁇ metal alkyl sulphate has a formula
  • the surfactant(s) is preferably a sodium alkyl sulphate, for example sodium lauryl sulphate.
  • the granule may also comprise conventional granulating aids such as polyvinylpyrrolidone such as KoUidon K12-30 (Trade Mark) or the proprietary hydroxymethyl cellulose material "Pha ⁇ nacoat 603" (Trade Mark), fillers / spheronising aids such as colloidal silica such as Aerosil 200 (Trade Mark) and/or cellulose derivatives such as microcrystalline cellulose, e.g. Avicel (Trade Mark).
  • a salt of clavulanic acid e.g. potassium clavulanate either as the sole beta-lactamase inhibitor content or in admixture with other beta-lactamase inhibitors then it is preferred that the granule also contains an amino acid, suitably glycine.
  • the relative proportions of the above components in the granule are suitably as follows.
  • Antibiotic, beta-lactamase inhibitors or combination thereof 50 wt. % or more e.g. 80% or more.
  • Surfactant 0.5 - 5 wt. % e.g. 0.5 - 1.5 wt. %.
  • Granulating aid 0 - 7.5 wt. %, typically if the granule comprises or contains a salt of clavulanic acid as the sole or principal active ingredient content or in admixture with another antibiotic 3 - 7.5 wt. %, e.g. 4 ⁇ 1 wt. %.
  • Fillers/spheronising aids 0 - 25 wt.
  • % e.g. 0 - 10 wt. % . If an amino acid is present in the granule, for example together with a salt of clavulanic acid, then suitably 1 - 50 wt. %, e.g. 5 - 15 wt. %. may be present. These weight percentages are expressed as total granule weight.
  • the shape of the granules is preferably substantially spherical, as defined above, with a size range between 10-44 mesh, e.g. 12-30 mesh.
  • the invention further provides a process for the preparation of a pharmaceutical granule, comprising admixing one or more beta-lactam antibiotics, and/or one or more beta-lactamase inhibitors with one or more surfactants which are Group I or Group ⁇ metal (CJO- ⁇ ) alkyl sulphates, and then granulating the mixture.
  • These granules may be prepared by a granulation process comprising for example mixing the milled ingredients with a suitable liquid, or by mixing the milled ingredients less the granulating aid with a solution or suspension of the granulating aid, followed by extrusion and preferably spheronisation, e.g. "marumerisation".
  • the suitable liquid may be an organic liquid or water
  • a suitable liquid may be an organic liquid such as an isopropyl alcohol: methylene dichloride mixture, typically in a 1:2-3 volume: volume ratio.
  • Salts of clavulanic acid such as potassium clavulanate are extremely water sensitive, so it is important that such salts are handled in extremely dry conditions, suitably 30% RH or less. It has been found that spheronised granules, such as marums may conveniently be prepared using the above formulations and process.
  • the granules of this invention are suited to coating, for example with water-resistant or enteric coatings. This is particularly so in the case of granules of the invention in which the active ingredient comprises or includes a salt of clavulanic acid.
  • the invention also provides a granule as described above, coated with a coating, which may be an at least partly water-resistant, suitably an enteric, coating.
  • the invention also provides a process wherein a granule as described above is coated with a coating, which may be an at least partly water-resistant, suitably an enteric, coating.
  • a coating which may be an at least partly water-resistant, suitably an enteric, coating.
  • An enteric coating may for example be an essentially conventional enteric coating material known for coating antibiotic granules.
  • Suitable coating materials are pharmaceutically acceptable methacrylic acid copolymers such as those described in the USP/NF, and such polymers of types A, B and C as described therein may be suitable.
  • Suitable generic classes and specific examples of pharmaceutically acceptable methacrylic acid copolymer are known polymers which are copolymers of acrylic and methacrylic esters with a low content of quaternary ammonium groups, for example having a molar ratio of such ammonium groups : remaining (meth)acrylic esters of 1 : _ ⁇ . 10, for example around 1 : 20 or 1 : 40, and with a mean molecular weight of around 150000.
  • Such polymers correspond to USP/NF 2 "Ammonio methacrylate copolymers, Type A and Type B".
  • methacrylic acid copolymer examples include polymers which are copolymers, anionic in character, based on methacrylic acid and methyl methacrylate, for example having a ratio of free carboxyl groups : methyl-esterified carboxyl groups of 1 : >3, e.g. around 1 : 1 or 1 : 2, and with a mean molecular weight of 135000.
  • Such polymers are sold under the trade name Eudragit TM, such as the Eudragit L series e.g. Eudragit L 12.5 TM, Eudragit L 12.5P TM, Eudragit L100 TM, Eudragit L 100-55 TM, Eudragit L-30 TM, Eudragit L-30 D-55 TM, the Eudragit S TM series e.g. Eudragit S 12.5, Eudragit S 12.5P TM, Eudragit S100 TM, the Eudragit NETM series e.g Eudragit NE 30D TM, the Eudragit RL TM series, e.g.
  • enteric polymers the term "enteric polymer” is a term of the art referring to a polymer which is preferentially soluble in the less acid environment of the intestine relative to the more acid environment of the stomach), for example having a solubility in aqueous media at pH 5.5 and above.
  • enteric polymers the term "enteric polymer” is a term of the art referring to a polymer which is preferentially soluble in the less acid environment of the intestine relative to the more acid environment of the stomach, for example having a solubility in aqueous media at pH 5.5 and above.
  • enteric polymers the term "enteric
  • the coating may be applied using either an aqueous medium or a non- aqueous medium such as an organic liquid, for example a methanol: methylene dichloride mixture.
  • a non-aqueous medium may be more suitable if the active ingredient comprises or contains a clavulanate salt.
  • the choice of plasticiser will depend upon whether an aqueous or non-aqueous medium is used, for example suitable plasticisers for an aqueous medium include propylene glycol, triethyl citrate or acetyl triethyl citrate, and for a non-aqueous medium include these and also dibutyl or diethyl phthalate.
  • the coating may also include an anti-tack agent such as talc or silica.
  • the enteric coating may be applied using an essentially conventional method, for example dissolving or suspending the enteric coating material in the medium, then spraying the solution or suspension onto the granules, followed by drying and screening.
  • the granules of this invention may be made up into pharmaceutical formulations in a conventional manner, e.g. by packing into sachets or other containers, or by tabletting, e.g. by a conventional process of compaction to provide a tablet formulation.
  • the invention therefore also provides a tablet which includes the above-described granules.
  • the invention also provides a process for the use of a granule as described above in the manufacture of a medicament for the treatment of bacterial infections.
  • the invention also provides a method of treatment of bacterial infections in humans and animals which comprises the administration of a therapeutically effective amount of granules as described above.
  • the invention also provides pharmaceutical granules as described above for use in the treatment of bacterial infections.
  • AerosU 200 1.0 Enteric coat
  • the first four ingredients were granulated using water and then enteric coated using methylene dichloride/methanol (60/40 v/v).
  • the first four ingredients were granulated using methylene dichloride/methanol (70/30 v/v). and then enteric coated using methanol/methylene dichloride (40/60 v/v).
  • Amoxycillin trihydrate 4900g Colloidal silica (Aerosil 200) 25g Sodium lauryl sulphate 50g Granulating solution
  • Coating The constituents of the coating suspension are mixed until uniform.
  • the vessel of a fluidised bed coater previously fitted with a spray gun for co-current application is loaded with 1kg granules.
  • the bed is warmed for a few minutes with warm inlet air. Spray the coating suspension untU sufficient coat is applied.
  • the constituents of the coating suspension are mixed unt ⁇ uniform using a high shear mixer (e.g. SUverson).
  • a high shear mixer e.g. SUverson
  • the vessel of a fluid bed granulator having previously been fitted widi a spray gun for co-current application, is loaded with an appropriate weight of marums.
  • the bed of marums is warmed for 5 minutes at an air inlet temperature of 40 °C.
  • the coating suspension is sprayed at a flow rate of approximately 3 to 4 L per minute at an atomising pressure of 0.2 bar. Sufficient coat is applied so that the coated marums meet the following dissolution requirements.
  • the clavulanate is essentially not released at pH 2 and 4 (preferably less than 10% of the clavulanate content being released of this pH), and achieve almost total release (greater than 80% , and preferably greater than 90%) by the end of the test at pH 7.
  • the coated marums are dried for 10-15 minutes at 40°C.
  • the dried, coated marums are screened and those between 10 and 12 mesh are retained.

Abstract

Pharmaceutical formulations, in particular beta-lactam antibiotic formulations in the form of substantially spherical granules, using a metal alkyl sulphate as a spheronizing agent.

Description

Pharmaceutical formul ations contai ng beta-l actam antibiotics and an al kyl sulp hate surfactant . *
This invention relates to pharmaceutical formulations, in particular to beta-lactam antibiotic formulations in the form of substantially spherical granules. In the manufacture of pharmaceutical formulations in which the active ingredient comprises a beta-lactam antibiotic and/or beta-lactamase inhibitor, it is frequently necessary to provide the formulation in the form of granules, for example for making up into tablets, capsules or sachet formulations etc. For certain applications in particular when such granules have to be coated, for example with a water-resistant or enteric coating to delay dissolution after oral ingestion, it is desirable that the granules are substantially spherical.
The term "substantially spherical" as used herein is intended to include spherical, ellipsoidal, e.g. of eccentricity up to no more than 2, preferably up to no more than 1.5, oblate spheroidal, e.g. having its longest axes up to no more than 2 times, preferably up to no more than 1.5 times longer than its shortest axis, polyhedral with at least 12 faces having predominantly curved rather than angular edges, and substantially equiaxial. The term also includes the shape of what are known in the art as "maru s". The terms "spheronised" and "spheronisation" are terms of the art. It is particularly desirable to have substantially spherical granules when granules of relatively water soluble antibiotics, and of beta-lactamase inhibitors such as salts of clavulanic acid such as potassium clavulanate are to be coated, as the angles of angular granules can present weak points in the coat via which the antibiotic or inhibitor may be leached out. Problems have been encountered in providing such antibiotics and beta-lactamase inhibitors in the form of granules, particularly in the form of substantially spherical granules.
According to this invention, there is provided a pharmaceutical granule, comprising: an active ingredient which comprises one or more beta-lactam antibiotics and/or one or more beta-lactamase inhibitors; and one or more surfactants which are Group I or Group II metal (CJO-17) alkyl sulphates.
The invention further provides a process for the preparation of a pharmaceutical granule, comprising admixing one or more beta-lactam antibiotics, and/or one or more beta-lactamase inhibitors with one or more surfactants which are Group I or Group π metal (Cιo-17) alkyl sulphates, and then granulating the mixture.
The granule is primarily intended for oral administration, and consequently preferred antibiotics are orally absorbed penicillins (which term includes penicillins penems, penams, carbapenems etc.) or cephalosporins. Preferred beta-lactam antibiotics are amoxycϋlin, for example as its trihydrate, and ampicillin. A preferred beta-lactamase inhibitor is a salt of clavulanic acid, especially group I metal salts thereof such as potassium clavulanate. A preferred combination of beta-lactamase inhibitor and antibiotic is potassium clavulanate : amoxycillin, as amoxycillin trihydrate or sodium amoxycillin, for example as crystalline anhydrous sodium amoxycillin as described in EP 0131147. A preferred ratio of clavulanate : amoxycillin is in the range 1 : 1 to 1 : 12 inclusive, particularly 1 : 2 to 1: 8, expressed in terms of weight ratios of the free acids. Suitably the Group I or Group π metal alkyl sulphate has a formula
[(CnH2n+ i)SO4"]mMm+ where M is a group I or π metal cation of ionic charge m and n is an integer between 10 and 17. The surfactant(s) is preferably a sodium alkyl sulphate, for example sodium lauryl sulphate.
The granule may also comprise conventional granulating aids such as polyvinylpyrrolidone such as KoUidon K12-30 (Trade Mark) or the proprietary hydroxymethyl cellulose material "Phaπnacoat 603" (Trade Mark), fillers / spheronising aids such as colloidal silica such as Aerosil 200 (Trade Mark) and/or cellulose derivatives such as microcrystalline cellulose, e.g. Avicel (Trade Mark). When the granule comprises or contains a salt of clavulanic acid, e.g. potassium clavulanate either as the sole beta-lactamase inhibitor content or in admixture with other beta-lactamase inhibitors then it is preferred that the granule also contains an amino acid, suitably glycine.
The relative proportions of the above components in the granule are suitably as follows. Antibiotic, beta-lactamase inhibitors or combination thereof: 50 wt. % or more e.g. 80% or more. Surfactant: 0.5 - 5 wt. % e.g. 0.5 - 1.5 wt. %. Granulating aid: 0 - 7.5 wt. %, typically if the granule comprises or contains a salt of clavulanic acid as the sole or principal active ingredient content or in admixture with another antibiotic 3 - 7.5 wt. %, e.g. 4 ± 1 wt. %. Fillers/spheronising aids 0 - 25 wt. % e.g. 0 - 10 wt. % . If an amino acid is present in the granule, for example together with a salt of clavulanic acid, then suitably 1 - 50 wt. %, e.g. 5 - 15 wt. %. may be present. These weight percentages are expressed as total granule weight.
The shape of the granules is preferably substantially spherical, as defined above, with a size range between 10-44 mesh, e.g. 12-30 mesh. The invention further provides a process for the preparation of a pharmaceutical granule, comprising admixing one or more beta-lactam antibiotics, and/or one or more beta-lactamase inhibitors with one or more surfactants which are Group I or Group ϋ metal (CJO-Π) alkyl sulphates, and then granulating the mixture.
These granules may be prepared by a granulation process comprising for example mixing the milled ingredients with a suitable liquid, or by mixing the milled ingredients less the granulating aid with a solution or suspension of the granulating aid, followed by extrusion and preferably spheronisation, e.g. "marumerisation". When the antibiotic comprises a relatively water-insoluble antibiotic such as amoxycillin trihydrate the suitable liquid may be an organic liquid or water, and when the antibiotic comprises a relatively water-soluble antibiotic such as clavulanate a suitable liquid may be an organic liquid such as an isopropyl alcohol: methylene dichloride mixture, typically in a 1:2-3 volume: volume ratio. Salts of clavulanic acid, such as potassium clavulanate are extremely water sensitive, so it is important that such salts are handled in extremely dry conditions, suitably 30% RH or less. It has been found that spheronised granules, such as marums may conveniently be prepared using the above formulations and process.
The granules of this invention, especially substantially spherical granules, are suited to coating, for example with water-resistant or enteric coatings. This is particularly so in the case of granules of the invention in which the active ingredient comprises or includes a salt of clavulanic acid.
Therefore the invention also provides a granule as described above, coated with a coating, which may be an at least partly water-resistant, suitably an enteric, coating.
The invention also provides a process wherein a granule as described above is coated with a coating, which may be an at least partly water-resistant, suitably an enteric, coating.
An enteric coating may for example be an essentially conventional enteric coating material known for coating antibiotic granules.
Suitable coating materials are pharmaceutically acceptable methacrylic acid copolymers such as those described in the USP/NF, and such polymers of types A, B and C as described therein may be suitable. Suitable generic classes and specific examples of pharmaceutically acceptable methacrylic acid copolymer are known polymers which are copolymers of acrylic and methacrylic esters with a low content of quaternary ammonium groups, for example having a molar ratio of such ammonium groups : remaining (meth)acrylic esters of 1 : _≥. 10, for example around 1 : 20 or 1 : 40, and with a mean molecular weight of around 150000. Such polymers correspond to USP/NF 2 "Ammonio methacrylate copolymers, Type A and Type B". Further suitable generic classes and specific examples of pharmaceutically acceptable methacrylic acid copolymer are known polymers which are copolymers, anionic in character, based on methacrylic acid and methyl methacrylate, for example having a ratio of free carboxyl groups : methyl-esterified carboxyl groups of 1 : >3, e.g. around 1 : 1 or 1 : 2, and with a mean molecular weight of 135000.
Such polymers are sold under the trade name Eudragit ™, such as the Eudragit L series e.g. Eudragit L 12.5 ™, Eudragit L 12.5P ™, Eudragit L100 ™, Eudragit L 100-55 ™, Eudragit L-30 ™, Eudragit L-30 D-55 ™, the Eudragit S ™ series e.g. Eudragit S 12.5, Eudragit S 12.5P ™, Eudragit S100 ™, the Eudragit NE™ series e.g Eudragit NE 30D ™, the Eudragit RL ™ series, e.g. Eudragit RL 12.5 ™, Eudragit RL 100 β, Eudragit RL PO ™, Eudragit RL 30D ™, and the Eudragit RS ™ series e.g. Eudragit RS 12.5 ™, Eudragit RS 100 ™, Eudragit RS PO™, and Eudragit RS 30D™ . Some of these polymers are known enteric polymers (the term "enteric polymer" is a term of the art referring to a polymer which is preferentially soluble in the less acid environment of the intestine relative to the more acid environment of the stomach), for example having a solubility in aqueous media at pH 5.5 and above. These Eudragit polymers may be used either alone or with a plasticiser. The coating may be applied using either an aqueous medium or a non- aqueous medium such as an organic liquid, for example a methanol: methylene dichloride mixture. A non-aqueous medium may be more suitable if the active ingredient comprises or contains a clavulanate salt. The choice of plasticiser will depend upon whether an aqueous or non-aqueous medium is used, for example suitable plasticisers for an aqueous medium include propylene glycol, triethyl citrate or acetyl triethyl citrate, and for a non-aqueous medium include these and also dibutyl or diethyl phthalate. The coating may also include an anti-tack agent such as talc or silica. The enteric coating may be applied using an essentially conventional method, for example dissolving or suspending the enteric coating material in the medium, then spraying the solution or suspension onto the granules, followed by drying and screening.
The granules of this invention may be made up into pharmaceutical formulations in a conventional manner, e.g. by packing into sachets or other containers, or by tabletting, e.g. by a conventional process of compaction to provide a tablet formulation. The invention therefore also provides a tablet which includes the above-described granules. The invention also provides a process for the use of a granule as described above in the manufacture of a medicament for the treatment of bacterial infections.
The invention also provides a method of treatment of bacterial infections in humans and animals which comprises the administration of a therapeutically effective amount of granules as described above.
The invention also provides pharmaceutical granules as described above for use in the treatment of bacterial infections.
The following examples illustrate the invention.
Example 1 mg/dose
Amoxycillin trihydrate 300 f.a.
Colloidal silica 1.8
Sodium lauryl sulphate 3.6
KoUidon 25 (polyvinylpyrrolidone) 5.4
Eudragit L100 14.0
Propylene glycol 1.4) Solids from
AerosU 200 1.0) Enteric coat
The first four ingredients were granulated using water and then enteric coated using methylene dichloride/methanol (60/40 v/v).
Example 2 mg/dose
Potassium clavulanate 150 f.a.
Pharmacoat 603 9
Colloidal sUica 3.4
Glycine 22.5
Sodium lauryl sulphate 2.3
Eudragit L100 152.1)
Diethyl phthalate 19.1) Solids from
Talc 22.8) Enteric coat
The first four ingredients were granulated using methylene dichloride/methanol (70/30 v/v). and then enteric coated using methanol/methylene dichloride (40/60 v/v). Example 3 mg/dose
Potassium clavulanate 1002.0g.
Pharmacoat 603 48.0g
Colloidal silica 18.0g
Glycine 120.0g
Sodium lauryl sulphate 12.0g
Granulating mixture:
Isopropyl alcohol 300ml Methylene dichloride 700ml Eudragit L100 334g Diethyl phthalate 42g Talc 50g
Methanol 2000ml Methylene dichloride 3000ml
Process
Screen the potassium clavulanate 16 mesh. Screen the Aerosil and Pharmacoat 20 mesh. Blend all ingredients in a planetary mixer for 5 minutes, then granulate with the granulating mixture. (The above weights of solid ingredients require approximately 460ml. of granulating mixture.) Extrude the granules through a 1mm. aperture and marumerise, wetting the particles slightly with granulating mixture as necessary. Dry the marums in a fluid bed dryer for 45 minutes at 45 °C. Screen the marums, retaining those between 12 and 30 mesh. Prepare die coating solution by dispersing the Eudragit in the methylene dichloride using a high speed mixer. Add the methanol and stir until the solution clears. Add the diethylphthalate and talc. Stir for 15 minutes. Load the marums into a coating pan and warm for at least 15 minutes. Spray the coating solution on the tumbling marum bed at about 25 ml/min. 15 litres of solution was sprayed on to 2100 g. of marums. Screen the dried, coated marums.
Example 4
Amoxycillin trihydrate 4900g Colloidal silica (Aerosil 200) 25g Sodium lauryl sulphate 50g Granulating solution
Polyvinylpyrrolidone (KoUidon 25, 75g
Trade Mark) •
Water 1463g
Coating solution
Eudragit L100 (Trade Mark) 200g
Colloidal silica 15g
Propylene glycol 20g
Dichloromethane 1800g
Methanol 1200g
Process
Blend the amoxyciUin trihydrate, colloidal silica and sodium lauryl sulphate in a planetary blender. This is wet massed with the granulating solution, and the resulting granules are extruded at medium speed on a (EXKS-1) extruder fitted with a 0.7 mm screen. The extrudate is then spheronised at fast speed on the Marumeriser, allowing a residence time for extrudates of 1-2 minutes. Marums are dried in a fluid bed drier for 2 hours at 60°C in divided lots of 2-3kg. These are subsequently blended and the fraction < 14#>30# retained.
Coating The constituents of the coating suspension are mixed until uniform. The vessel of a fluidised bed coater previously fitted with a spray gun for co-current application is loaded with 1kg granules. The bed is warmed for a few minutes with warm inlet air. Spray the coating suspension untU sufficient coat is applied.
Exar nple 5
1 Potassium clavulanate 1002.0g
2 Pharmacoat 603 48.0g
3 Colloidal silica 18.0g
4 Glycine 120.0g
5 Sodium lauryl sulphate 12.0g
Granulating solution
6 Isopropyl alcohol 300ml
7 Methylene dichloride 700ml Coating suspens siioonn
%w/w
8 Eudragit L300 52.2 9 Citroflex A2 (acetyltriethylcitrate) 1.6
(equivalent to 10% dry lacquer)
10 Talc 7.8 11 Water 38.4
Process
Screen the potassium clavulanate through 16 mesh screen. Screen the colloidal sUica and Pharmacoat through 20 mesh screen
Blend all the ingredients in a planetary mixer for 5 minutes, then granulate with the granulating solution. (The weights above require approximately 460ml of solution). Extrude die granules through a 1mm aperture and marumerise, wetting the particles slightly with granulating solution as necessary. Dry the marums in a fluid bed drier for 45 minutes at 40°C. Screen the marums, retaining those between 12 and 30 mesh.
Coating
The constituents of the coating suspension are mixed untϋ uniform using a high shear mixer (e.g. SUverson).
The vessel of a fluid bed granulator, having previously been fitted widi a spray gun for co-current application, is loaded with an appropriate weight of marums.
The bed of marums is warmed for 5 minutes at an air inlet temperature of 40 °C. The coating suspension is sprayed at a flow rate of approximately 3 to 4 L per minute at an atomising pressure of 0.2 bar. Sufficient coat is applied so that the coated marums meet the following dissolution requirements. The clavulanate is essentially not released at pH 2 and 4 (preferably less than 10% of the clavulanate content being released of this pH), and achieve almost total release (greater than 80% , and preferably greater than 90%) by the end of the test at pH 7.
Note: approximately 400g of coating suspension (= 63g of solids) is needed for each lOOg of marums.
The coated marums are dried for 10-15 minutes at 40°C. The dried, coated marums are screened and those between 10 and 12 mesh are retained.

Claims

Claims:
1. A pharmaceutical granule, comprising: an active ingredient which comprises one or more beta-lactam antibiotics and/or one or more beta-lactamase inhibitors; and one or more surfactants which are Group I or Group π metal (CJO- 17) alkyl sulphates.
2. A pharmaceutical granule according to claim 1 characterised in that the antibiotic is selected from amoxycUlin and ampiciUin, and the beta-lactamase inhibitor is a salt of clavulanic acid.
3. A pharmaceutical granule according to claim 2 characterised in that the beta-lactamase inhibitor is potassium clavulanate and the antibiotic is amoxycillin
4. A pharmaceutical granule according to any one of claims 1 to 3 characterised in that the surfactant(s) is a sodium alkyl sulphate.
5. A pharmaceutical granule according to claim 4 characterised in that the surfactant is sodium lauryl sulphate.
6. A pharmaceutical granule according to any one of claims 2 to 5 characterised in that the granule also contains an amino acid.
7. A pharmaceutical granule according to any one of claims 1 to 6 characterised in that the relative proportions of the components in the granule are: antibiotic, beta-lactamase inhibitors or combination thereof: 50 wt. % or more; surfactant: 0.5 - 5 wt. %; granulating aid: 0 - 7.5 wt. %; fillers/spheronising aids 0 - 25 wt. % expressed as total granule weight.
8. A pharmaceutical granule according to any one of claims 1 to 7 coated with a coating which may be an at least partly water-resistant.
9. A process for the manufacture of a pharmaceutical granule, comprising admixing one or more beta-lactam antibiotics, and/or one or more beta-lactamase inhibitors with one or more surfactants which are Group I or Group II metal (CJO- 17) alkyl sulphates, and then granulating the mixture.
10. A process wherein a granule according to any one of claims 1 to 7 is coated with an at least partly water resistant coating.
11. A pharmaceutical tablet which includes granules according to any one of claims 1 to 8.
12. A process characterised in that granules according to any one of claims 1 to 8 are compacted into a pharmaceutical tablet.
13. A process for the use of a granule according to any one of claims 1 to 8 in the manufacture of a medicament for the treatment of bacterial infections.
14. A method of treatment of bacterial infections in humans and animals which comprises the administration of a therapeutically effective amount of granules according to any one of claims 1 to 8.
PCT/EP1995/001039 1994-03-24 1995-03-20 Pharmaceutical formulations containing beta-lactam antibiotics and an alkyl sulphate surfactant WO1995025516A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP95928859A EP0751771A1 (en) 1994-03-24 1995-03-20 Pharmaceutical formulations containing beta-lactam antibiotics and an alkyl sulphate surfactant
JP7524382A JPH09510470A (en) 1994-03-24 1995-03-20 Pharmaceutical formulations containing beta-lactam antibiotics and alkyl sulphate surfactants

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9405856.7 1994-03-24
GB9405856A GB9405856D0 (en) 1994-03-24 1994-03-24 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
WO1995025516A1 true WO1995025516A1 (en) 1995-09-28

Family

ID=10752439

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/001039 WO1995025516A1 (en) 1994-03-24 1995-03-20 Pharmaceutical formulations containing beta-lactam antibiotics and an alkyl sulphate surfactant

Country Status (4)

Country Link
EP (1) EP0751771A1 (en)
JP (1) JPH09510470A (en)
GB (1) GB9405856D0 (en)
WO (1) WO1995025516A1 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035672A1 (en) * 1997-02-14 1998-08-20 Smithkline Beecham Laboratoires Pharmaceutiques Pharmaceutical formulations comprising amoxocyllin and clavulanate
WO1998040054A1 (en) * 1997-03-12 1998-09-17 Astra Aktiebolag (Publ) An enteric coated oral dosage form comprising sodium amoxycillin
WO2001047499A1 (en) * 1999-12-23 2001-07-05 Smithkline Beecham P.L.C. Pharmaceutical formulations comprising sodium amoxycillin and potassium clavulanate
WO2002083129A2 (en) * 2001-04-12 2002-10-24 Sandoz Gmbh Pharmaceutical composition comprising clavulanic acid
US6660299B2 (en) 1999-04-13 2003-12-09 Beecham Pharmaceuticals Limited Modified release pharmaceutical formulation comprising amoxycillin
US6726908B2 (en) 1995-09-07 2004-04-27 Smithkline Beecham P.L.C. Pharmaceutical formulation
US6746692B2 (en) 1999-04-13 2004-06-08 Beecham Pharmaceuticals (Pte) Limited Modified release pharmaceutical formulation comprising amoxycillin
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
US6783773B1 (en) 1999-04-13 2004-08-31 Beecham Pharmaceuticals (Pte) Limited Composition comprising amoxicillin and potassium clavulanate
AT412344B (en) * 2001-04-12 2005-01-25 Sandoz Ag Pharmaceutical composition useful for reducing rapid degradation of the active ingredient comprises clavulanate, in the form of granulated and hydrophobised particles, and an active ingredient
US7011849B2 (en) 2000-10-12 2006-03-14 Beecham Pharmaceuticals (Pte) Limited Second release phase formulation
WO2006072577A1 (en) * 2005-01-07 2006-07-13 Sandoz Ag Process for preparing granulates comprising amoxicillin
AT413983B (en) * 2001-04-12 2006-08-15 Sandoz Ag Pharmaceutical composition useful for reducing rapid degradation of the active ingredient comprises clavulanate, in the form of granulated and hydrophobised particles, and an active ingredient
CN112587481A (en) * 2020-12-28 2021-04-02 成都中牧生物药业有限公司 Alkalescent amoxicillin soluble powder and preparation method thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2459014C (en) * 2001-09-14 2010-08-10 Scolr, Inc. Amino acid modulated extended release dosage form
MX2010004556A (en) * 2007-10-26 2010-07-01 Rexahn Pharmaceuticals Inc Pharmaceutical formulation of clavulanic acid.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2523446A1 (en) * 1982-03-19 1983-09-23 Dietlin Francois Controlled release pharmaceutical compsns. - for oral admin. contg. konjak mannan(s) and surfactant
US4602012A (en) * 1984-01-03 1986-07-22 Glaxo Group Limited Cephalosporin antibiotics
EP0293975A1 (en) * 1987-05-27 1988-12-07 Akzo N.V. Dry, rapidly soluble, compositions of beta-lactam antibiotics
EP0411952A2 (en) * 1989-08-04 1991-02-06 McNEIL-PPC, INC. Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
WO1991016893A1 (en) * 1990-04-27 1991-11-14 Beecham Group Plc Pharmaceutical formulation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2523446A1 (en) * 1982-03-19 1983-09-23 Dietlin Francois Controlled release pharmaceutical compsns. - for oral admin. contg. konjak mannan(s) and surfactant
US4602012A (en) * 1984-01-03 1986-07-22 Glaxo Group Limited Cephalosporin antibiotics
EP0293975A1 (en) * 1987-05-27 1988-12-07 Akzo N.V. Dry, rapidly soluble, compositions of beta-lactam antibiotics
EP0411952A2 (en) * 1989-08-04 1991-02-06 McNEIL-PPC, INC. Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
WO1991016893A1 (en) * 1990-04-27 1991-11-14 Beecham Group Plc Pharmaceutical formulation

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6726908B2 (en) 1995-09-07 2004-04-27 Smithkline Beecham P.L.C. Pharmaceutical formulation
WO1998035672A1 (en) * 1997-02-14 1998-08-20 Smithkline Beecham Laboratoires Pharmaceutiques Pharmaceutical formulations comprising amoxocyllin and clavulanate
WO1998040054A1 (en) * 1997-03-12 1998-09-17 Astra Aktiebolag (Publ) An enteric coated oral dosage form comprising sodium amoxycillin
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US7250176B1 (en) 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US7217430B2 (en) 1999-04-13 2007-05-15 Beecham Pharmaceuticals (Pte) Limited Compositions and methods of treatment comprising amoxicillin and potassium clavulanate with xanthan
US6660299B2 (en) 1999-04-13 2003-12-09 Beecham Pharmaceuticals Limited Modified release pharmaceutical formulation comprising amoxycillin
US6746692B2 (en) 1999-04-13 2004-06-08 Beecham Pharmaceuticals (Pte) Limited Modified release pharmaceutical formulation comprising amoxycillin
US6783773B1 (en) 1999-04-13 2004-08-31 Beecham Pharmaceuticals (Pte) Limited Composition comprising amoxicillin and potassium clavulanate
WO2001047499A1 (en) * 1999-12-23 2001-07-05 Smithkline Beecham P.L.C. Pharmaceutical formulations comprising sodium amoxycillin and potassium clavulanate
US7011849B2 (en) 2000-10-12 2006-03-14 Beecham Pharmaceuticals (Pte) Limited Second release phase formulation
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
AT412344B (en) * 2001-04-12 2005-01-25 Sandoz Ag Pharmaceutical composition useful for reducing rapid degradation of the active ingredient comprises clavulanate, in the form of granulated and hydrophobised particles, and an active ingredient
AT413983B (en) * 2001-04-12 2006-08-15 Sandoz Ag Pharmaceutical composition useful for reducing rapid degradation of the active ingredient comprises clavulanate, in the form of granulated and hydrophobised particles, and an active ingredient
WO2002083129A3 (en) * 2001-04-12 2003-03-06 Biochemie Gmbh Pharmaceutical composition comprising clavulanic acid
WO2002083129A2 (en) * 2001-04-12 2002-10-24 Sandoz Gmbh Pharmaceutical composition comprising clavulanic acid
WO2006072577A1 (en) * 2005-01-07 2006-07-13 Sandoz Ag Process for preparing granulates comprising amoxicillin
CN112587481A (en) * 2020-12-28 2021-04-02 成都中牧生物药业有限公司 Alkalescent amoxicillin soluble powder and preparation method thereof
CN112587481B (en) * 2020-12-28 2022-03-15 成都中牧生物药业有限公司 Alkalescent amoxicillin soluble powder and preparation method thereof

Also Published As

Publication number Publication date
GB9405856D0 (en) 1994-05-11
JPH09510470A (en) 1997-10-21
EP0751771A1 (en) 1997-01-08

Similar Documents

Publication Publication Date Title
CA2382098C (en) Sustained-release, oral pharmaceutical forms of administration
US5997905A (en) Preparation of pharmaceutically active particles
KR100767928B1 (en) Method for making granules with masked taste and instant release of the active particle
US6096340A (en) Omeprazole formulation
WO1995025516A1 (en) Pharmaceutical formulations containing beta-lactam antibiotics and an alkyl sulphate surfactant
FI88675B (en) ELASTIC FILM OVERDRAWING
EP1318792B1 (en) Sustained release composition containing clarithromycin
SK16302000A3 (en) ENTERIC COATED PHARMACEUTICAL COMPOSITION AND METHOD OFì (54) MANUFACTURING
KR20010074914A (en) Omeprazole formulation
AU748299B2 (en) Medicinal compositions adhering to stomach/duodenum
CZ295893B6 (en) Granulate and fast-disintegrating and fast-dissolving composition
US6623758B2 (en) Cephalosporin-metronidazole antibiotic composition
WO2004087111A1 (en) Oral taste masked pharmaceutical compositions
US5837277A (en) Palatable pharmaceutical compositions
US5897877A (en) Oral pharmaceutical preparation containing erythromycin base
CA2478121A1 (en) Antibiotic composition
US5492700A (en) Process and composition for the development of controlled release gemfibrozil dosage form
PL180979B1 (en) Carbamazepinic form of a drug with retarded release of biologically active substance
AU6224699A (en) Taste masking coating compositions
JP2003531115A (en) Antibiotic compositions with inhibitors
EP0570606A1 (en) Orally administrable solid medicine and process for preparing the same
EP0956006A1 (en) Colonic delivery of weak acid drugs
JP3456211B2 (en) Long-acting formulation
US5358723A (en) Process and composition for the development of controlled release gemfibrozil dosage form
BG64499B1 (en) Pharmaceutical adhesive compositions to stomach and/or duodenum

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: US

Ref document number: 1996 716274

Date of ref document: 19960924

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1995928859

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995928859

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995928859

Country of ref document: EP